Therapeutic Advances in First-Line Management of Acute Myeloid Leukemia.
Over the past several years, drug approvals for first-line treatment of acute myeloid leukemia have changed the landscape from a "wasteland" to an "embarrassment of riches." In general, patients deemed "fit" for induction chemotherapy who have a core-binding factor abnormality should receive 7 + 3 in combination with gemtuzumab, 7 + 3 with midostaurin for those with an FLT3 abnormality, and liposomal cytarabine + daunorubicin for patients with secondary AML. Although other options exist, Dr. Daniel A. Pollyea recommended a venetoclax/azacitidine regimen for newly diagnosed "unfit" patients. Future research should focus on more clearly determining the definition of a "fit" patient, he said at the NCCN 2019 Annual Congress: Hematologic Malignancies.